Recent performance snapshot

Trevi Therapeutics (TRVI) has been on many watchlists after a strong past 3 months, even as the stock has drifted down over the past month and past week.

Shares last closed at US$13.50, giving the company a market value of about US$1.89b. The stock is up over the past year and over the past 3 years, but has been weaker over the past month.

Recent trading has cooled, with a 7 day share price return of about 3% lower and a 30 day share price return of roughly 7% lower. However, the 90 day share price return of nearly 15% and a very large 3 year total shareholder return suggest longer term momentum has been much stronger than the latest pullback.

If Trevi’s move has you looking beyond a single stock, this is a good moment to widen your search with our screener of 39 healthcare AI stocks

With Trevi still loss making yet carrying a roughly US$1.9b valuation and a price well below some published targets, the key question is simple: are you seeing a genuine opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 38% Undervalued

Against the last close at $13.50, the most followed narrative points to a fair value near $21.64, framing Trevi as materially undervalued on that view.

Growing recognition of chronic cough in idiopathic pulmonary fibrosis and other interstitial lung diseases as a distinct, undertreated symptom area with no FDA approved therapies, alongside approximately 150,000 IPF patients and an estimated 228,000 non IPF ILD patients where a material subset have uncontrolled cough, positions Haduvio in a therapy class that could directly influence future revenue potential if clinical programs succeed.

Analysts are building this valuation on a single drug, multiple chronic cough indications and a long runway of projected cash, earnings and margins that all have to line up. Want to see which specific revenue path and profit profile sit behind that fair value and how far they stretch current expectations.

Result: Fair Value of $21.64 (UNDERVALUED)

However, this hinges on Haduvio delivering clean late stage data, and any trial setback or larger than expected capital raise could quickly challenge that undervaluation story.

Next Steps

With both upside potential and clear concerns on the table, this is the moment to move quickly, review the full picture, and weigh the 1 key reward and 4 important warning signs.

Looking for more investment ideas?

If Trevi has caught your attention, do not stop here. Broaden your watchlist with other clear, data backed ideas that could suit your style.

• Target potential upside by scanning screener containing 21 high quality undiscovered gems that pair solid fundamentals with relatively low market attention.
• Strengthen your downside protection by reviewing 62 resilient stocks with low risk scores built around companies with more resilient risk profiles.
• Prioritise financial resilience by focusing on solid balance sheet and fundamentals stocks screener (46 results) that combine sturdier balance sheets with underlying business quality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.